Confronting Emerging Viral Challenges—Comprehensively Providing Validation Services for Ebola Virus Antigen and Nucleic Acid Testing
Confronting Emerging Viral Challenges—Comprehensively Supporting Ebola Virus Antigen and Nucleic Acid Testing Testing Verification Service
In a biosafety laboratory that meets national requirements
Supports Sudan, Zaire, and Bundibugyo ebolaviruses. Verification Service
Ebola Virus Disease (EVD) is an acute infectious disease caused by infection with the Ebola virus. It is characterized by rapid transmission and a high case-fatality rate. According to the “Diagnosis and Treatment Protocol for Ebola Virus Disease (2026 Edition)” and relevant authoritative literature [1–3], rapid and accurate etiological testing is a critical component for achieving “early detection, early reporting, early isolation, and early treatment,” among which… The coverage of different subtypes and the reliability of diagnostic reagents It is directly related to the effectiveness of epidemic prevention and control.
Therefore, the development and registration of Ebola virus test kits cannot be separated from… The authentic viral strain is maintained under compliant biosafety conditions. Systematic verification.
Jiangsu Ningpu, leveraging a biosafety laboratory that meets national standards, has officially begun offering services for handling the Ebola virus. and Hantaan virus, among others Antigen/Nucleic Acid Test Kit Validation Services, covering major circulating subtypes:
- Sudan Ebola virus (SUDV)
- Zaire ebolavirus (EBOV)
- Bundibugyo ebolavirus (BDBV)
The verification services we offer include:
- Precision Verification: In‑batch and Inter‑batch Repeatability Testing
- Inclusive Validation: Verification of Coverage Across Different Viral Subtypes, Strains, and Sequences
- Sensitivity Validation: Gradient Dilution Assay for the Limit of Detection (LoD), Combined with Evaluation Using Clinical Positive Samples at Different Ct Values
- Specificity Verification: Cross-Reactivity and Interference Substance Testing
Service format:
Customize validation protocols based on kit type (antigen testing, Nucleic acid Testing, etc.)
Applicable to:
IVD reagent R&D companies are required to submit additional performance data when applying for registration.
Evaluation of Public Health Emergency Reserve Products
Why choose Jiangsu Ningpu?
Qualification Compliance: Partner Organizations Complies with national requirements for the management of pathogenic microorganism laboratories.
Complete subtyping: covering all subtypes, including Sudan, Zaire, and Bundibugyo.
Project Focus: Performance evaluation of test kits, with data applicable to regulatory registration and quality control.
Controllable cycles: Generate reports on demand, with expedited options available.
References:
[1] Li Lanjuan. Ebola Virus Disease [M]. Hangzhou: Zhejiang University Press, 2015.
[2] Yuan Min, Lu Hongzhou. Scientific Prevention and Control of Ebola Virus Disease [J]. Chinese Journal of Infectious Diseases, 2014, 32(9): 515–516.
[3] Chen Ye, Wang Ping, Liu Fangwei, et al. Advances in research on Ebola hemorrhagic fever [J]. Chinese Journal of Public Health, 2017.
Validation data represent the minimum standard for kit quality and provide the foundation of confidence for regulatory submissions.
Jiangsu Ningpu provides a “trustworthy, traceable, and compliant” verification closed-loop for Ebola diagnostic products.
2022-07-26
xy13584019024